Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Practice Management LLC

Neither a doctor nor a teaching hospital

Research payments

$5,832,566

1,353 payments

Through program year 2025, Total Practice Management LLC is reported as receiving $5,832,566 in research payments, across 1,353 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$949,750	308
2024	Research	$923,645	357
2023	Research	$1,733,232	406
2022	Research	$1,875,897	251
2021	Research	$10,690	8
2020	Research	$63,218	2
2019	Research	$276,134	21

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $3,995,176 766 payments
Apellis Pharmaceuticals, Inc. $1,212,035 492 payments
EyePoint Pharmaceuticals US, Inc. $183,229 9 payments
Ocular Therapeutix, Inc. $166,549 19 payments
RxSight Inc $78,000 17 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $76,058 2 payments
Astellas Pharma Global Development $73,756 41 payments
Regeneron Pharmaceuticals, Inc. $17,501 1 payment
Roche TCRC, Inc. $12,900 1 payment
AbbVie, Inc. $11,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $1,202,236 145 payments
Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $625,477 143 payments
Port Delivery System of Ranibizumab Extension Study $613,040 140 payments
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $365,467 187 payments
Va2 Phiii $341,774 21 payments
Va2 Phiii Yosemite $300,674 18 payments
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration $252,002 198 payments
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $251,689 30 payments
Faricimab Dme Long Term Extension Rhone X $226,160 86 payments
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $151,028 49 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.